DexCom (DXCM) versus Hancock Jaffe Laboratories (HJLI) Financial Review
DexCom (NASDAQ:DXCM) and Hancock Jaffe Laboratories (NASDAQ:HJLI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.
Valuation & Earnings
This table compares DexCom and Hancock Jaffe Laboratories’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DexCom||$1.03 billion||10.37||-$127.10 million||$0.30||396.27|
|Hancock Jaffe Laboratories||$190,000.00||152.77||-$13.04 million||N/A||N/A|
This table compares DexCom and Hancock Jaffe Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Hancock Jaffe Laboratories||-6,921.70%||N/A||-274.92%|
This is a breakdown of recent recommendations and price targets for DexCom and Hancock Jaffe Laboratories, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Hancock Jaffe Laboratories||0||0||0||0||N/A|
DexCom currently has a consensus target price of $149.53, indicating a potential upside of 25.79%. Given DexCom’s higher possible upside, equities analysts clearly believe DexCom is more favorable than Hancock Jaffe Laboratories.
Institutional and Insider Ownership
97.9% of DexCom shares are held by institutional investors. Comparatively, 1.5% of Hancock Jaffe Laboratories shares are held by institutional investors. 1.8% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
DexCom beats Hancock Jaffe Laboratories on 8 of the 10 factors compared between the two stocks.
DexCom Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Hancock Jaffe Laboratories Company Profile
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.